Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Symposium Webinar: Use of the Kinetically Derived Maximum Dose in Toxicity Testing Presentations
September 30, 2020

Welcome and Introductions 
Nicole Kleinstreuer, Ph.D., NICEATM

Use and Evaluation of KMD Data at USEPA's Office of Pesticide Programs
Anna Lowit, Ph.D., EPA

Current State-of-play: OECD Discussions on Doses Selection in Chronic Toxicity Studies
Anne Gourmelon, OECD

Problem Formulation: Background, Motivation, and Expected Outcomes
Michelle Embry, Ph.D., Health and Environmental Sciences Institute

Maximum Tolerated Dose: Concepts and Background
Chad Blystone, Ph.D., DABT, NTP

Concepts of Non-linear Pharmacokinetics and KMD
Alan Boobis, Ph.D., Imperial College London

Implications of Non-linear PK in Toxicity Testing and Interpretation of Dose-response Data
Salil Pendse, Nuventra, Inc.

Determining an Inflection Point from External-internal Dose Data
Philip Villanueva, EPA

Estimating Human Exposures and Comparison to Doses Used in Testing
Jeff Dawson, EPA

Dose Setting and Considerations for the 3Rs
Fiona Sewell, Ph.D., National Centre for the Replacement Refinement & Reduction of Animals in Research

Integration of TK into Toxicity Studies and Dose Level Setting
Jean Domoradzki, Ph.D., DABT, Corteva Agriscience

Integrating KMD/TK Data with MoA and Other Information in a Weight of Evidence Approach
Harvey Clewell, Ph.D., Ramboll